{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:19:22Z","timestamp":1767989962286,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,9,3]],"date-time":"2017-09-03T00:00:00Z","timestamp":1504396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.tranon.2017.09.009","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T06:46:50Z","timestamp":1507963610000},"page":"949-955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study"],"prefix":"10.1016","volume":"10","author":[{"given":"Liangyou","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2017.09.009_bb0005","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.tranon.2017.09.009_bb0010","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU Guidelines on Renal Cell Carcinoma: 2014 Update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0015","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/jso.24575","article-title":"A proposal of post-operative nomogram for overall survival in patients with renal cell carcinoma and venous tumor thrombus","volume":"115","author":"Gu","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0020","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0025","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2015.12.001","article-title":"Robot-assisted laparoscopic inferior vena cava thrombectomy: different sides require different techniques","volume":"69","author":"Wang","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0030","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.eururo.2007.05.009","article-title":"A critical analysis of surgery for kidney cancer with vena cava invasion","volume":"52","author":"Kirkali","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0035","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1634\/theoncologist.2014-0105","article-title":"Adjuvant therapy for renal cell carcinoma: past, present, and future","volume":"19","author":"Pal","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2017.09.009_bb0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tranon.2017.09.009_bb0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tranon.2017.09.009_bb0050","first-page":"2016","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2017.09.009_bb0055","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tranon.2017.09.009_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2004.04897.x","article-title":"The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus","volume":"94","author":"Blute","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.tranon.2017.09.009_bb0065","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.urolonc.2012.04.019","article-title":"Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence","volume":"31","author":"Zhao","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0070","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.urology.2011.06.044","article-title":"Duplicated vena cava with tumor thrombus from renal cancer: use of venogram for safer operative planning","volume":"79","author":"Abbasi","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.tranon.2017.09.009_bb0075","doi-asserted-by":"crossref","first-page":"E87","DOI":"10.1111\/bju.13268","article-title":"Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis","volume":"117","author":"Abel","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.tranon.2017.09.009_bb0080","doi-asserted-by":"crossref","first-page":"112 e15","DOI":"10.1016\/j.urolonc.2014.11.009","article-title":"Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma","volume":"33","author":"Lane","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0085","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2011.02.032","article-title":"The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus","volume":"59","author":"Cost","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00345-013-1088-1","article-title":"Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?","volume":"32","author":"Bigot","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.tranon.2017.09.009_bb0095","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2017.09.009_bb0100","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","article-title":"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy","volume":"104","author":"Ebos","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2017.09.009_bb0105","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-12-0002","article-title":"Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients","volume":"18","author":"Griffioen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2017.09.009_bb0110","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1535-7163.MCT-09-1106","article-title":"Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study","volume":"9","author":"Hammers","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.tranon.2017.09.009_bb0115","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2016.11.034","article-title":"Updated European Association of Urology guidelines regarding adjuvant therapy for renal cell carcinoma","volume":"71","author":"Bex","year":"2017","journal-title":"Eur Urol"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523317303170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523317303170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:33:20Z","timestamp":1761834800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523317303170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1936523317303170"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2017.09.009","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2017.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}